Small molecule · Activator of phenylalanine hydroxylase (PAH) · developed by Ptc Therap
Sepiapterin is a precursor of the enzymatic cofactor tetrahydrobiopterin (BH4), which activates phenylalanine hydroxylase (PAH). It is used to treat hyperphenylalaninemia in sepiapterin-responsive phenylketonuria, given alongside a phenylalanine-restricted diet.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 24, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06302348 | Phase 3 | Phenylketonuria | Recruiting | PTCT |
| NCT05166161 | Phase 3 | Phenylketonuria | Completed | PTCT |
| NCT03712124 | Phase 2 | Gastroparesis | Completed | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
GastroparesisPhenylketonuria
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.
See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTCT catalysts and pipeline →